Monitoring Crohn’s disease during anti-TNF-α therapy: validation of the magnetic resonance enterography global score (MEGS) against a combined clinical reference standard

• DOI: 10.1007/s00330-015-4036-1
• Publication Date: 2015-10-03T10:10:34Z
• Authors: Davide Prezzi; Gauraang Bhatnagar; Roser Vega; Jesica Makanyanga; Steve Halligan; Stuart Andrew Taylor
• Keywords: Crohn’s disease; Adult; Male; Adolescent; Tumor Necrosis Factor-alpha; 610; Reproducibility of Results; Therapeutic monitoring; Middle Aged; Magnetic Resonance Imaging; Gastrointestinal Tract; Young Adult; 03 medical and health sciences; Magnetic resonance imaging; Treatment Outcome; 0302 clinical medicine; Crohn Disease; Humans; Biological therapy; Female; Enterography; Biomarkers; Retrospective Studies

To assess the ability of magnetic resonance enterography global score (MEGS) to characterise Crohn's disease (CD) response to anti-TNF-α therapy.Thirty-six CD patients (median age 26 years, 20 males) commencing anti-TNF-α therapy with concomitant baseline MRI enterography (MRE) were identified retrospectively. Patients' clinical course was followed and correlated with subsequent MREs. Scan order was randomised and MEGS (a global activity score) was applied by two blinded radiologists. A physician's global assessment of the disease activity (remission, mild, moderate or severe) at the time of MRE was assigned. The cohort was divided into clinical responders and non-responders and MEGS compared according to activity status and treatment response. Interobserver agreement was assessed.Median MEGS decreased significantly between baseline and first follow-up in responders (28 versus 6, P < 0.001) but was unchanged in non-responders (26 versus 18, P = 0.28). The median MEGS was significantly lower in clinical remission (9) than in moderate (14) or severe (29) activity (P < 0.001). MEGS correlated significantly with clinical activity (r = 0.53; P < 0.001). Interobserver Bland-Altman limits of agreement (BA LoA) were -19.7 to 18.5.MEGS decreases significantly in clinical responders to anti-TNF-α therapy but not in non-responders, demonstrates good interobserver agreement and moderate correlation with clinical disease activity.• MRI scores of Crohn's activity are used increasingly in clinical practice and therapeutic trials. • Such scores have been advocated as biomarkers of therapeutic response. • MEGS reflects clinical response to anti-TNF-α therapy and the clinical classification of disease activity. • MEGS demonstrates good interobserver agreement.